Why This Matters

Anticoagulants have a narrow therapeutic index. Even modest changes in drug levels can shift a patient from therapeutic to supratherapeutic range, dramatically increasing bleeding risk. Antibiotics are among the most commonly prescribed drugs and interact with anticoagulants through multiple mechanisms.

Warfarin Interactions

Warfarin is metabolised primarily by CYP2C9. Antibiotics that inhibit CYP2C9 increase warfarin levels:

High-risk combinations:

• •Metronidazole — inhibits CYP2C9 and CYP3A4; can double INR within 3–5 days
• •Fluconazole — potent CYP2C9 inhibitor; INR can triple
• •Ciprofloxacin — moderate CYP1A2 inhibition; also reduces gut flora (vitamin K)
• •Trimethoprim-sulfamethoxazole — inhibits CYP2C9; also displaces warfarin from albumin

Management: Reduce warfarin dose by 25–50% when starting these antibiotics. Check INR 3–5 days after starting and after stopping.

DOAC Interactions

DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are substrates of P-glycoprotein (P-gp) and CYP3A4.

Azithromycin: P-gp inhibitor — increases DOAC levels by 20–30%. Clinically significant in patients at high bleeding risk. Rifampicin: Potent P-gp and CYP3A4 inducer — reduces DOAC levels by 50–75%. Avoid combination or switch to warfarin with close INR monitoring. Clarithromycin/Erythromycin: CYP3A4 inhibitors — increase rivaroxaban and apixaban levels significantly. Use azithromycin instead when possible.

Practical Management

• →Always check interactions before prescribing antibiotics to anticoagulated patients
• →Warfarin patients: Check INR 3–5 days after starting and stopping interacting antibiotics
• →DOAC patients: Consider dose reduction or temporary switch for high-risk combinations
• →Duration matters: Short courses (3–5 days) carry lower risk than prolonged courses
• →Document: Record the interaction and your management plan in the notes

The ClinicalCalc Drug Interaction Checker

Use the Drug Interaction Checker on ClinicalCalc Pro to screen all antibiotic-anticoagulant combinations before prescribing. The tool provides severity classification (major/moderate/minor) and specific clinical recommendations.